News

FDA grants breakthrough therapy status to nipocalimab for Sjögren’s disease

Johnson & Johnson’s antibody-based therapy candidate nipocalimab has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for treating adults with moderate to severe Sjögren’s disease. This status is meant to accelerate the development and regulatory review of investigational therapies intended to treat serious…

Experimental Sjögren’s therapy shows potential in early lab studies

KB-7898, Kronos Bio’s investigational therapy for Sjögren’s disease, was shown to lower antibody production and the release of inflammatory molecules in lab studies involving cell and animal models of autoimmune conditions, the company announced. Kronos is planning further preclinical studies to assess KB-7898’s safety and pharmacological properties…

Imaging test to measure salivary gland damage may help in diagnosis

An imaging test that measures damage to salivary glands may effectively be used, together with the presence of self-reactive antibodies, to diagnose Sjögren’s disease and determine disease staging. That’s according to a new study from China that investigated the use of the imaging test, called parotid sialography, alongside one…